Market Overview
The UAE pharmaceutical market size reached USD 4.45 Billion in 2025. The market is projected to expand significantly, with expectations to reach USD 8.59 Billion by 2034. This growth is driven by the escalating prevalence of chronic diseases, substantial government investments in healthcare infrastructure, and the growing demand for innovative therapies. The forecast period spans 2026-2034, with a compound annual growth rate (CAGR) of 7.01%. Pharmaceutical drugs dominate by type with a 71.6% share, Conventional leads by nature at 88.4%, and Dubai commands the largest regional share at 39.7% in 2025.
How the New Emirates Drug Establishment is Reshaping the Future of UAE Pharmaceutical Market:
- The UAE’s growing focus on domestic drug security is driving a significant shift toward centralized regulatory oversight, with the Emirates Drug Establishment officially launched at the World Health Expo 2026 (WHX 2026) to drive domestic drug production and strengthen long-term medical supply sustainability.
- The Emirates Drug Establishment introduced a new mechanism on February 24, 2026, requiring pharmaceutical companies to appoint more than one authorized local agent per product, ending reliance on single-agent distribution arrangements under Federal Decree-Law No. 38 of 2024.
- Julphar reported strong H1 2026 results, driven by improved profitability, revenue growth, and a strengthened balance sheet, with consistent sales growth and accelerated deleveraging reinforcing the Ras Al Khaimah-based manufacturer’s position as the UAE’s largest Arab pharmaceutical company.
- Sharjah continued advancing three new pharmaceutical factories specializing in respiratory products, eye drops, antibiotics, and first aid materials, all powered by advanced manufacturing technologies and artificial intelligence, reinforcing the emirate’s growing manufacturing footprint.
- Innovations in AI-driven drug discovery and biosimilar development are gaining traction across the UAE in 2026, with research centers in Masdar City and M42 pioneering precision medicine as clinical trials have risen 40% since 2023.
Grab a sample PDF of this report: https://www.imarcgroup.com/uae-pharmaceutical-market/requestsample
Market Growth Factors
The rising burden of chronic diseases is a central driver of the pharmaceutical market’s expansion. Conditions including type 2 diabetes, cardiovascular disease, hypertension, obesity, and various forms of cancer now account for the majority of the national disease burden, generating consistent demand for long-term pharmaceutical treatments, specialty medications, and preventive drug regimens.
Government healthcare investments and local manufacturing initiatives are reshaping the region’s pharmaceutical landscape. Through the National Strategy for the Pharmaceutical Industry, the Dubai Industrial Strategy 2030, and the broader Vision 2031 framework, the government has deployed incentive programs including tax exemptions, manufacturing grants, and fast-track licensing pathways within free zones such as Dubai Science Park and KIZAD.
Medical tourism growth and strategic geographic positioning are creating favorable conditions for sustained market growth. Dubai and Abu Dhabi have emerged as main pharmaceutical distribution centers for the Middle East, Africa, and South Asian regions, enabled by high-quality port facilities and efficient air freight services through Dubai International Airport. These developments are further strengthening the pharmaceutical industry in uae, supporting efficient supply chain operations and expanding the country’s role as a regional pharmaceutical hub.
Market Segmentation
Type Insights:
- Pharmaceutical Drugs (Cardiovascular, Dermatology, Gastrointestinal, Genito-Urinary, Hematology, Anti-Infective, Metabolic Disorder, Musculoskeletal Disorder, Central Nervous System, Oncology, Ophthalmology, Respiratory Diseases Drugs)
- Biologics (Monoclonal Antibodies, Therapeutic Proteins, Vaccines)
Nature Insights:
- Organic
- Conventional
Regional Insights:
- Dubai
- Abu Dhabi
- Sharjah
- Others
Recent Development & News
- April 2026: Insilico Medicine in Masdar City develops the UAE’s first fully AI-discovered drug candidate, ISM0387, completing the process in under 12 months and targeting solid tumours including aggressive brain cancers.
- June 2026: The UAE becomes the first country outside the United States to commercially launch the oral Wegovy (semaglutide) pill, offering a needle-free GLP-1 option for chronic weight management.
- August 2026: The Emirates Drug Authority approves Rinvok as the world’s first authorised treatment for non-segmental vitiligo in patients aged 12 and older.
If you require any specific information that is not currently covered within the scope of the report, we will provide the same as part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assaessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302